Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2

被引：85

作者：

Yu, Fei ^{[1
]}

Xiang, Rong ^{[1
]}

Deng, Xiaoqian ^{[1
]}

Wang, Lili ^{[2
]}

Yu, Zhengsen ^{[1
]}

Tian, Shijun ^{[1
]}

Liang, Ruiying ^{[1
]}

Li, Yanbai ^{[1
]}

Ying, Tianlei ^{[3
]}

Jiang, Shibo ^{[3
]}

机构：

[1] Hebei Agr Univ, Coll Life Sci, Baoding, Peoples R China

[2] Hebei Agr Univ, Res Ctr Chinese Jujube, Baoding, Peoples R China

[3] Fudan Univ, Sch Basic Med Sci, CAMS, Key Lab Med Mol Virol,MOE,NHC, Shanghai, Peoples R China

来源：

SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2020年 / 5卷 / 01期

基金：

中国国家自然科学基金;

关键词：

ACUTE RESPIRATORY SYNDROME; CORONAVIRUS SPIKE PROTEIN; POTENT NEUTRALIZATION; VIRUS; IMMUNOPROPHYLAXIS; IDENTIFICATION; GENERATION; EPITOPES; FRAGMENT; VACCINE;

D O I：

10.1038/s41392-020-00318-0

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The outbreaks of severe acute respiratory syndrome (SARS) and Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV and SARS-CoV-2, respectively, have posed severe threats to global public health and the economy. Treatment and prevention of these viral diseases call for the research and development of human neutralizing monoclonal antibodies (NMAbs). Scientists have screened neutralizing antibodies using the virus receptor-binding domain (RBD) as an antigen, indicating that RBD contains multiple conformational neutralizing epitopes, which are the main structural domains for inducing neutralizing antibodies and T-cell immune responses. This review summarizes the structure and function of RBD and RBD-specific NMAbs against SARS-CoV and SARS-CoV-2 currently under development.

引用

页数：12

共 50 条

[41] A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
Liu, Hejun
Yuan, Meng
Huang, Deli
Bangaru, Sandhya
Zhao, Fangzhu
Lee, Chang-Chun D.
Peng, Linghang
Barman, Shawn
Zhu, Xueyong
Nemazee, David
Burton, Dennis R.
van Gils, Marit J.
Sanders, Rogier W.
Kornau, Hans-Christian
Reincke, S. Momsen
Pruss, Harald
Kreye, Jakob
Wu, Nicholas C.
Ward, Andrew B.
Wilson, Ian A.
CELL HOST & MICROBE, 2021, 29 (05) : 806 - +
[42] A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
Yuan, Meng
Wu, Nicholas C.
Zhu, Xueyong
Lee, Chang-Chun D.
So, Ray T. Y.
Lv, Huibin
Mok, Chris K. P.
Wilson, Ian A.
SCIENCE, 2020, 368 (6491) : 630 - +
[43] Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies
Ye, Farong
Zhao, Jie
Xu, Peng
Liu, Xinliang
Yu, Jing
Shangguan, Wei
Liu, Jiazhi
Luo, Xiaosheng
Li, Cheng
Ying, Tianlei
Wang, Jing
Yu, Biao
Wang, Ping
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2021, 60 (23) : 12904 - 12910
[44] Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine
Deliyannis, Georgia
Gherardin, Nicholas A.
Wong, Chinn Yi
Grimley, Samantha L.
Cooney, James P.
Redmond, Samuel J.
Ellenberg, Paula
Davidson, Kathryn C.
Mordant, Francesca L.
Smith, Tim
Gillard, Marianne
Lopez, Ester
McAuley, Julie
Tan, Chee Wah
Wang, Jing J.
Zeng, Weiguang
Littlejohn, Mason
Zhou, Runhong
Chan, Jasper Fuk-Woo
Chen, Zhi-wei
Hartwig, Airn E.
Bowen, Richard
Mackenzie, Jason M.
Vincan, Elizabeth
Torresi, Joseph
Kedzierska, Katherine
Pouton, Colin W.
Gordon, Tom P.
Wang, Lin-fa
Kent, Stephen J.
Wheatley, Adam K.
Lewin, Sharon R.
Subbarao, Kanta
Chung, Amy W.
Pellegrini, Marc
Munro, Trent
Nolan, Terry
Rockman, Steven
Jackson, David C.
Purcell, Damian F. J.
Godfrey, Dale I.
EBIOMEDICINE, 2023, 92
[45] Distinct Differences in the Interactions of Receptor Binding Domains of SARS-CoV-2 and SARS-CoV with Human ACE2
Acharyal, Atanu
Pavlova, Anna
Chipot, Christophe J.
Gumbart, James C.
BIOPHYSICAL JOURNAL, 2021, 120 (03) : 299A - 299A
[46] A Novel Conserved Linear Neutralizing Epitope on the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein
Hua, Rong-Hong
Zhang, Shu-Jian
Niu, Bei
Ge, Jin-Ying
Lan, Ting
Bu, Zhi-Gao
MICROBIOLOGY SPECTRUM, 2023, 11 (04):
[47] Identification of a potent SARS-CoV-2 neutralizing nanobody targeting the receptor-binding domain of the spike protein
Liu, Chen
Hadiatullah, Hadiatullah
Yuchi, Zhiguang
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 281
[48] Duration of SARS-CoV-2 Serum-Neutralizing Antibodies Against SARS-CoV-2 Dependent on the Individual
Li, Jin
Zou, Li
Li, Shaojie
Zou, Ruogu
Fang, Zhixiong
Zhang, Pingan
Li, Huijun
Wang, Shanshan
Ke, Dong
Gao, Peng
Jin, Cuicui
Fang, Cong
Zhou, Ji
He, Ellen
Skog, Sven
VIRAL IMMUNOLOGY, 2023, 36 (03) : 153 - 162
[49] Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine
He, YX
Zhou, YS
Liu, SW
Kou, ZH
Li, WH
Farzan, M
Jiang, SB
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 324 (02) : 773 - 781
[50] Broadly neutralizing antibodies against SARS-CoV-2 variants
Linqi Zhang
NationalScienceOpen, 2022, 1 (01) : 24 - 31

← 1 2 3 4 5 →